CD80 and neoplasm: Such vesicles, in turn, can be modified by MP with immune stimulatory molecules, i.e., B7.1 (102), targeting molecules or additional tumor antigens, i.e., HER2 (35), to induce, direct, and/or increase anti-tumor immune responses.